TL1A, commonly called TNFSF15, belongs to the tumor necrosis factor family. TL1A is expressed in a variety of immune cells, including monocytes, macrophages, dendritic cells, T cells, and others.

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

It is also the first and only randomized, blinded and placebo-controlled phase 2 study to investigate the impact of TL1A in CD. In the study, patients who met pre-specified inclusion criteria were ...

will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug ...

Duvakitug is an important asset for both Sanofi and Teva. It’s one of a class of drugs that target a protein called TL1A, which is implicated in the inflammation seen in diseases like Crohn’s and ...

One of these, the TL1A pathway, plays a key role in driving inflammation and fibrosis in various autoimmune diseases, making its inhibition a promising strategy for multiple indications, including ...

Pipeline developments are expected to play a crucial role in Teva’s future. The upcoming Phase 2 top-line results for Anti-TL1A in Q4 2024 and the advancement of Duvakitug’s subcutaneous formulation ...

Immune cells rely on cell-cell communication to specify and fine-tune their responses. They express an extensive network of cell communication modes, including a vast repertoire of cell surface and ...

Ebi3, Epstein–Barr virus (EBV)-induced gene 3; ERK, extracellular regulated protein kinases; NF-κB, nuclear factor-kappa B; AP-1, activator protein-1; JAK2, janus kinase 2; STAT1, signal transducer ...

LONDON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- After success in centralized exchange (CEX) trading, Mizar, the automated trading platform backed by Nexo, KuCoin, and other notable traders, is expanding its ...